Cargando…
Clinical utility of tumour marker velocity of cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) in breast cancer surveillance
BACKGROUND: Serum tumour markers, cancer antigen 15–3 (CA 15–3) and carcinoembryonic antigen (CEA) are not routinely recommended for detecting breast cancer recurrence and monitoring treatment. In this study, we aim to evaluate the diagnostic accuracy of absolute CA 15–3 and CEA levels and report on...
Autores principales: | Hing, J.X., Mok, C.W., Tan, P.T., Sudhakar, S.S., Seah, C.M., Lee, W.P., Tan, S.M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375621/ https://www.ncbi.nlm.nih.gov/pubmed/32485607 http://dx.doi.org/10.1016/j.breast.2020.05.005 |
Ejemplares similares
-
Carcinoembryonic antigen (CEA) "fingerprints".
por: Rule, A. H., et al.
Publicado: (1973) -
A monkey antigen crossreacting with carcinoembryonic antigen, CEA.
por: Engvall, E., et al.
Publicado: (1976) -
First British standard for carcinoembryonic antigen (CEA).
por: Laurence, D. J., et al.
Publicado: (1975) -
Immunochemical studies of carcinoembryonic antigen (CEA) variants.
por: Ichiki, A. T., et al.
Publicado: (1976) -
Epitopes of carcinoembryonic antigen (CEA) defined by monoclonal antibodies.
por: Price, M. R.
Publicado: (1988)